Ladenburg Thalmann Rates Alterity Therapeutics (ATHE) buy

Ladenburg Thalmann has upgraded Alterity Therapeutics, setting a new price target of $10, a 102.84% upside from the current price.

By EarningsIQ Research Desk · Published Jun 17, 2026, 2:02 AM EDT · Updated Jun 23, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Ladenburg Thalmann rated Alterity Therapeutics Limited ($ATHE) "buy" with a $10 price target on June 16, 2026.

Since the rating, $ATHE is up 6.7% after 1 week, up 9.5% after 1 month and down 43.7% to date (from the $4.65 close on Jun 16, 2026).

ATHE Alterity Therapeutics Limited

$2.62 -17.09% year to date

Daily close · Oct 16, 2026

Key Points

Ladenburg Thalmann raised its rating on Alterity Therapeutics to 'buy' with a $10 price target on June 16, 2026.
Ladenburg Thalmann's $10 price target implies 102.84% upside from Alterity Therapeutics Limited's ($ATHE) current $4.93 share price.
Shares of Alterity Therapeutics traded at $4.41, with a market cap of approximately $84.3 million and a 52-week range between $2.66 and $7.00.
Alterity Therapeutics, focused on neurodegenerative disorders, has a strong buy consensus with a mean target price of $11.00 from analysts.

Get $ATHE trade alerts by text

We text you when insiders, Congress or big funds trade $ATHE. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Alterity Therapeutics Limited alert may contain errors. Disclosures

On June 16, 2026, Ladenburg Thalmann raised its rating on Alterity Therapeutics Limited (NasdaqCM: ATHE) to a 'buy', setting a new price target of $10. The upgrade reflects optimism about the company's prospects in the biotechnology sector, particularly in its work on neurodegenerative disorders.

Alterity Therapeutics Limited Stock Up 25.8%

Shares of NasdaqCM:ATHE traded near $4.41. Alterity Therapeutics has a market cap of about $84.3 million. Despite not being profitable, the company is actively involved in promising research, as evidenced by its negative forward P/E of -3.94. The stock's beta is -0.01, indicating low volatility compared to the market. Over the past year, the stock has ranged from $2.66 to $7.00, with a 50-day moving average of $4.28 and a 200-day moving average of $3.89.

12-month forecast

$ATHE price target

Alterity Therapeutics Limited daily closes and this analyst's $10 target. Not advice.

Other Institutional Activity in Alterity Therapeutics

Among Alterity Therapeutics' institutional investors, Twin Lakes Capital Management, LLC holds 139,258 shares valued at approximately $484,618, unchanged from previous reports. HB Wealth Management, LLC also maintained its position with 58,460 shares worth around $203,441. Meanwhile, Morgan Stanley reduced its holdings by 5,300 shares, leaving it with 58,382 shares valued at $203,170. Citadel Advisors LLC increased its position by 3,266 shares, now holding 20,077 shares worth $71,474.

Analysts Set New Price Targets

On June 16, 2026, Ladenburg Thalmann assumed coverage on Alterity Therapeutics with a 'buy' rating and a $10 price target. Previously, Maxim Group maintained a 'buy' rating with a $12 target on January 30, 2025. The consensus among analysts is a 'strong buy', with a mean price target of $11.00 based on two opinions.

About Alterity Therapeutics

Alterity Therapeutics Limited, based in Melbourne, Australia, is a biotechnology company focused on developing treatments for neurodegenerative disorders such as Parkinson's disease and Multiple System Atrophy. Led by CEO Dr. David A. Stamler, the company employs a small team of nine people. Its leading drug candidate, ATH434, is in Phase II clinical trials aimed at treating Parkinson's disease and other related disorders. Alterity also operates a drug discovery platform to develop new treatments for neurological diseases.

Bottom Line

Ladenburg Thalmann's upgrade to a 'buy' rating for Alterity Therapeutics highlights the potential seen in the company's pipeline for neurodegenerative treatments. Investors track such ratings closely as they provide insights into a company's future prospects. Remember that analyst ratings are forward-looking and subject to change based on new information.